First, the shape of it
Pacira’s filed numbers show a company generating three-quarters of a billion dollars in annual revenue, with gross margins that most manufacturers would envy. The stock trades at a price-to-sales ratio, meaning what the market pays per dollar of sales, that sits near the bottom quarter of the company’s own decade-long range. Yet the trailing earnings multiple, what the market pays per dollar of profit, sits near the top. Those two readings describe the same company at the same moment, and they cannot both be right. The gap between them is the story.
A drug born in the opioid crisis
Pacira spent most of the 2010s making a single argument to American hospitals: there is a better way to manage post-surgical pain than flooding a patient with opioids. Its answer was EXPAREL, an injectable form of a common local anesthetic wrapped in a microscopic fat bubble that releases slowly over three days. The pitch landed. By the time the opioid crisis had become a national emergency, EXPAREL was already in operating rooms across the country, and Pacira had built a business around the idea that non-opioid pain control was not just ethical but commercially durable.
Revenue grew strongly through the early part of the decade, a run that reflected both genuine clinical adoption and the tailwind of a healthcare system desperate to reduce narcotic prescribing. Then growth stalled. The 10-K for fiscal year 2023 showed revenue of $675 million, barely above the prior year, and earnings per share that had been swinging wildly depending on which costs landed in which quarter. The easy growth was over. The question became what kind of company Pacira would be next.
The year everything moved at once
Fiscal year 2024 answered that question uncomfortably. The 10-K for fiscal year 2024 recorded a meaningful per-share loss, the worst annual result in the company’s recent history, as restructuring charges and write-downs swamped operating performance. Management responded with a strategic reset it calls the “5×30 strategy,” a plan to concentrate resources on its biopharmaceutical pipeline rather than spreading capital across every product it owned.
The most visible move came on July 31, 2026, when Pacira completed the sale of its iovera° business to Zimmer Biomet for $73.6 million upfront, with additional milestone payments possible through 2031. Iovera° was a handheld device that used cold therapy to temporarily block pain nerves. It worked, but it was a device business sitting inside a drug company, and the distraction cost focus. Selling it was an admission that Pacira had been trying to be too many things.
The 10-K for fiscal year 2025 showed the reset beginning to take hold: revenue of $726 million and a thin profit after the prior year’s loss. Net margin of 1% is not something to celebrate, but the direction had reversed.
What the most recent quarter actually shows
The 10-Q for the quarter ended June 30, 2026, filed August 4, 2026, is the most current financial picture available. Total revenue came in at $192.4 million for the quarter, up 6% from the same period a year earlier. EXPAREL, still the engine, contributed the large majority of that, growing modestly on volume gains, meaning more vials shipped even as pricing faced some pressure from hospital group purchasing contracts. ZILRETTA, an injectable steroid for knee arthritis pain, added a smaller but growing share.
The gross margin, what remains of each revenue dollar after the direct cost of making and delivering the product, held at 77%. For context, a typical consumer goods company might keep roughly forty cents of every sales dollar at this stage; Pacira keeps nearly double that. That is the structural advantage of a drug with a protected formulation and no generic competition yet.
Operating income for the quarter was thin relative to revenue, which tells you where the money goes: selling, general, and administrative expenses, plus research and development, are consuming most of what the product economics generate. As outlined in the Q2 earnings call, those two overhead lines together could approach two-thirds of projected full-year revenue. A business with beautiful product margins and heavy overhead is a business betting that the overhead eventually pays off in new products or market share.
The cash position as of June 30, 2026, was $251 million, roughly equal to what the whole company earns in revenue across a single quarter. That is a meaningful cushion, though the dossier does not detail the debt load sitting on the other side of the balance sheet, so the net picture remains incomplete.
The pipeline bet
The overhead spending is, in large part, funding a gene therapy program. PCRX-201, which Pacira calls enekinragene inzadenovec, is an investigational treatment for knee osteoarthritis that works by delivering an anti-inflammatory gene directly into the joint. The idea is a single injection that reprograms the joint’s own cells to reduce inflammation for years, rather than a drug patients take repeatedly. In August 2026, Pacira announced publication of two-year Phase 1 data in the Annals of the Rheumatic Diseases, showing sustained improvements in pain and function. Phase 2 enrollment concluded in late 2025, and topline results are expected before the end of 2026.
Gene therapy for a condition as common as knee arthritis would be a large commercial opportunity if it works. It would also be expensive to develop and even more expensive to manufacture. The filed numbers cannot tell us whether PCRX-201 succeeds; they can only confirm that Pacira is spending real money on the attempt.
Meanwhile, a February 2026 analysis cited by Seeking Alpha argued that EXPAREL’s manufacturing complexity creates a meaningful barrier against generic entry, with a managed generic launch from a Fresenius settlement not expected until 2030. That gives Pacira several years of protected revenue from its core product, assuming the analysis holds.
What the price implies
Our data shows the stock’s price-to-sales ratio sitting in the bottom quarter of Pacira’s own decade-long range. By that measure, the market is paying less per dollar of Pacira’s sales than it has on most days over the past ten years. At the same time, the trailing price-to-earnings ratio stands far above the decade median, because the profit is so thin that even a small numerator produces a large ratio. The forward multiple, by contrast, sits at a fraction of that figure, because analysts expect profits to recover sharply. Those two numbers describe the same stock and the same disagreement.
In September 2026, at least two sell-side firms initiated or raised coverage on Pacira, per MarketBeat; the assumptions underlying those opinions, pipeline success and margin recovery, are not independently confirmable from the filed numbers reviewed here.
What the filed numbers do confirm: a company with durable product margins, a core drug facing no generic competition for several years, a balance sheet with meaningful cash, and a cost structure that is currently consuming most of what those margins generate. The math of the business and the mood of the market are both watching the same clinical readout. PCRX-201 results before year-end 2026 will either validate the overhead or expose it.
Reading the numbers
- Q2 2026 revenue: $192.4 million. What it is: total sales for the three months ending June 30, 2026, per the 10-Q filed August 4, 2026. What it means here: the business is growing modestly, about 6% above the same quarter a year ago. Everyday version: a shop that took in $181 last summer took in $192 this summer. Growth, but not acceleration.
- Gross margin: 77%. What it is: the share of each revenue dollar left after direct production costs. What it means here: the drug itself is highly profitable; the problem is everything spent after it leaves the factory. Everyday version: a bakery that buys flour for 23 cents and sells bread for a dollar has a 77-cent margin before paying the rent, the staff, and the delivery van.
- Operating income: $4.3 million on $192 million in revenue. What it is: what remains after selling costs and R&D are subtracted from gross profit. What it means here: the gap between a 77% gross margin and a 2% operating margin is almost entirely selling and research spending. Everyday version: the bakery keeps 77 cents per loaf before overhead, but after paying the van, the marketing, and the test kitchen, it keeps about two cents.
- P/E ratio: 142 times (trailing); the forward figure, per analyst consensus estimates cited in the dossier, is a fraction of that. What it is: the price tag per dollar of profit, trailing meaning based on the last twelve months of actual earnings, forward meaning based on projected earnings. What it means here: the trailing figure is high because profits are thin; the forward figure is lower because analysts project profit recovery, a projection that depends on assumptions about pipeline outcomes and cost discipline that the filed numbers cannot confirm. Everyday version: paying $142 for a machine that earned $1 last year; IF the machine earns substantially more next year as projected, the same price would represent a very different multiple, but only if that projection proves correct.
- Cash: $251 million as of June 30, 2026. What it is: liquid assets on hand. What it means here: roughly one quarter’s worth of revenue sitting in reserve, providing runway for the pipeline without an immediate need to raise new money. Debt levels were not fully detailed in the available filings, which limits the complete picture.
Sources
- 10-Q for quarter ended June 30, 2026 (SEC EDGAR)
- 10-Q for quarter ended March 31, 2026 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2025 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2024 (SEC EDGAR)
- 10-K for fiscal year ended December 31, 2023 (SEC EDGAR)
- Pacira Q2 2026 earnings release (GlobeNewswire, August 4, 2026)
- PCRX-201 Phase 1 two-year data announcement (GlobeNewswire, August 6, 2026)
- Q2 2026 earnings call transcript (Seeking Alpha)
- 2026 revenue guidance and EXPAREL coverage (Seeking Alpha)
- Analyst price targets and ratings (MarketBeat)
